Key result
Compared with non-diabetic patients, patients with diabetes post-MI had a higher risk of a composite of cardiovascular events.
Why the study?
Does diabetes influence cardiac remodeling and clinical outcomes, and does aliskiren improve LV size in diabetic patients post-MI with LVEF ≤ 45%?
RCT (n=820)
placebo-controlled
randomized
Does diabetes influence cardiac remodeling and clinical outcomes, and does aliskiren improve LV size in diabetic patients post-MI with LVEF ≤ 45%?
Diabetic patients post-MI with LV dysfunction have increased CV risk and greater diastolic dysfunction and concentric remodeling compared to non-diabetics, despite similar systolic impairment.
Answers are grounded in this paper and cite their sources.
Diabetics post-MI with LV dysfunction warrant closer CV surveillance; confirms higher risk and concentric remodeling while leaving aliskiren's ESV benefit open.
AIMS: We assessed the relationship between diabetes and cardiac structure and function following myocardial infarction (MI) and whether diabetes influences the effect of direct renin inhibition on change in left ventricular (LV) size. METHODS AND RESULTS: The ASPIRE trial enrolled 820 patients 2-8 weeks after MI with ejection fraction ≤ 45% and randomized them to the direct renin inhibitor aliskiren (n= 423) or placebo (n = 397) added to standard medical therapy. Echocardiography was performed at baseline and after 36 weeks in 672 patients with evaluable paired studies. Compared with non-diabetic patients, diabetic patients (n = 214) were at higher risk for a composite of cardiovascular (CV) death, heart failure hospitalization, recurrent MI, stroke, or aborted sudden death (14 vs. 7%; adjusted hazard ratio 1.63, 95% confidence interval 1.01-2.64, P= 0.045), despite similar left ventricular ejection fraction (37.9 ± 5.3 vs. 37.6 ± 5.2%, P= 0.48) and end-systolic volume (ESV) (84 ± 25 vs. 82 ± 28 mL, P= 0.46). Diabetic patients demonstrated greater concentric remodelling (relative wall thickness 0.38 ± 0.07 vs. 0.36 ± 0.07, P= 0.0002) and evidence of higher LV filling pressure (E/E' 11.1 ± 5.3 vs. 9.1 ± 4.3, P= 0.0011). At 36 weeks, diabetic patients experienced similar per cent reduction in ESV overall (-4.9 ± 17.9 vs. -5.5 ± 16.9, P= 0.67) but tended to experience greater reduction in ESV than non-diabetic patients when treated with aliskiren (interaction P = 0.08). CONCLUSIONS: Compared with non-diabetic patients, diabetic patients are at increased risk of CV events post-MI despite no greater LV enlargement or reduction in systolic function. Diabetic patients demonstrate greater concentric remodelling and evidence of higher LV filling pressure, suggesting diastolic dysfunction as a potential mechanism for the higher risk observed among these patients.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2011) conducted an RCT in myocardial infarction (n=820). Diabetes vs. Non-diabetic patients was evaluated on composite of cardiovascular (CV) death, heart failure hospitalization, recurrent MI, stroke, or aborted sudden death (HR 1.63, 95% CI 1.01-2.64, p=0.045). Compared with non-diabetic patients, patients with diabetes post-MI had a higher risk of a composite of cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: